Table 2.

Phenotypic Susceptibility Data Associated With the Most Common INI Resistance Mutation Patterns Present in 192 Virus Isolates From 105 Patients

Primary Mutations*	No. of Unique Viruses†		Published In vitro Susceptibility Data§
	Without accessory mutations	With accessory mutations	Raltegravir	Elvitegravir	S/GSK1349572
148H + 140S	26	18	>150 [2, 9, 11, 21–23]	>150 [2, 9, 11, 22–23]	3 [11]
148R + 140S	5	0	>150 [9, 11, 21, 23]	>150 [9, 23]	8 [11]
148R + 140A	2	1	>150 [21, 23]	>150 [23]	NA
148R	5	0	10 to 50 [8–9, 11, 21]	90 to 150 [8–9, 11]	1 [11]
148K	1	0	25 to 40 [2, 9–11, 21]	80 [2, 9–11]	1 [11]
Totals	39	19
155H	11	24	10 to 30 [8–11, 21–22]	20 to 50 [2, 8–11, 22]	1 [11]
155H + 92Q	1	2	80 to 150 [11, 21]	125 to 150 [2, 11]	3 [11]
Totals	12	26
143R	7	1	15 to 20 [11, 21]	2 [11]	1 [11]
143R + 97A	2	7	>150 [21]	NA	NA
143C + 97A	2	4	>150 [18, 21]	NA	NA
143C	0	2	3 to 4 [11, 21]	1.5 [11]	1 [11]
Totals	11	14

NOTE. The viral sequences in this table were obtained from 12 published references in the Stanford HIV Drug Resistance Database [32].

*G140SA and T97A are in this column because of their strong association with Q148 and Y143 mutations, respectively. Accessory mutations include the mutations in the second half of Table 1 (except G140SA and T97A). Viruses with primary mutations belonging to more than one pathway are not shown. ^†The totals of these 2 columns consist of 121 viruses containing one of the 3 most common raltegravir-associated mutational patterns. ^§In vitro susceptibility data obtained using the PhenoSense assay, the Antivirogram, or one of the generic HeLa-CD4⁺ reporter gene assay variants. Viruses containing G140 + Q148 mutations may have up 10- to 20-fold decreased S/GSK1349572 susceptibility when a third INI resistance mutation is present [11, 33].